|Bid||143.15 x 1100|
|Ask||145.00 x 1400|
|Day's Range||126.01 - 144.45|
|52 Week Range||91.46 - 249.73|
|Beta (5Y Monthly)||1.26|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 17, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||248.00|
Subscribe to Yahoo Finance Plus to view Fair Value for SWAVLearn more
Investment company Sugarloaf Wealth Management, LLC (Current Portfolio) buys BTC BlackRock Ultra Short-Term Bond ETF, PIMCO Dynamic Income Fund, iShares National Muni Bond ETF, Goldman Sachs Group Inc, Eagle Point Credit Co Inc, sells Vanguard Dividend Appreciation FTF, PIMCO Dynamic Credit & Mortgage Income Fund, Quadratic Interest Rate Volatility And Inflation H, Tesla Inc, Technology Select Sector SPDR ETF during the 3-months ended 2021Q4, according to the most recent filings of the investmen
Shares of the medtech company ShockWave Medical (NASDAQ: SWAV) rose by as much as 11.2% during the first four days of trading this week, according to data provided by S&P Global Market Intelligence. Over the weekend, Bloomberg News reported that fellow mid-cap medical device company Penumbra (NYSE: PEN) was exploring a merger with ShockWave. In response, ShockWave was said to be working with an advisor to study the feasibility of a tie-up with another healthcare company.
Shockwave Medical (SWAV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.